vs
Side-by-side financial comparison of IAMGOLD CORP (IAG) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
IAMGOLD CORP is the larger business by last-quarter revenue ($724.2M vs $619.8M, roughly 1.2× QuidelOrtho Corp).
Iamgold Corporation is a Canadian company that owns and operates gold mines in Burkina Faso and Canada. Headquartered in Toronto, the company was incorporated in 1990, and went public on the Toronto Stock Exchange in 1996, with additional shares being listed on the New York Stock Exchange beginning in 2005. The company formerly owned or had stakes in the Sadiola and Yatela gold mines in Mali, the Mupane gold mine in Botswana, the Niobec niobium mine in Quebec, as well as a royalty in the Diav...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
IAG vs QDEL — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $724.2M | $619.8M |
| Net Profit | — | $-91.8M |
| Gross Margin | 35.4% | — |
| Operating Margin | — | — |
| Net Margin | — | -14.8% |
| Revenue YoY | — | -10.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q3 25 | — | $699.9M | ||
| Q2 25 | $724.2M | $613.9M | ||
| Q1 25 | $338.9M | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | — | $727.1M | ||
| Q2 24 | $465.0M | $637.0M | ||
| Q1 24 | $226.2M | $711.0M |
| Q1 26 | — | $-91.8M | ||
| Q3 25 | — | $-733.0M | ||
| Q2 25 | — | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-147.7M | ||
| Q1 24 | — | $-1.7B |
| Q1 26 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | 31.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 19.1% | — |
| Q1 26 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% |
| Q1 26 | — | -14.8% | ||
| Q3 25 | — | -104.7% | ||
| Q2 25 | — | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | — | -2.7% | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | — | -239.9% |
| Q1 26 | — | $-1.35 | ||
| Q3 25 | — | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $-2.20 | ||
| Q1 24 | — | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | — | $1.9B |
| Total Assets | — | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q1 26 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.3B |
| Q1 26 | — | $5.6B | ||
| Q3 25 | — | $5.7B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.5B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.8B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IAG
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
